Léčivé přípravky pro kardiovaskulární systém XIV. Alirocumab
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| 16363299 | 08/31/2021 | sanofi-aventis, s.r.o. | 21,465,400.00 | 19,514,000.00 | 21,465,400.00 | 19,514,000.00 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| 461_Písemná zpráva.pdf | Písemná zpráva zadavatele | 09/21/2021, 02:50 PM | Dokument není zavirovaný |
List of Participants
| Show detail | |||||||
|---|---|---|---|---|---|---|---|
| sanofi-aventis, s.r.o. | Praha | 19,514,192.13 | CZK |
Price Actually Paid in Each Year of Performance
| 16363299 | 2023 | 6,422,912.30 | 5,839,011.18 |
| 16363299 | 2022 | 5,672,983.70 | 5,157,257.91 |
| 16363299 | 2021 | 2,054,325.77 | 1,867,568.85 |